investors

Marshall Edwards, Inc. (Nasdaq: MSHL) is focused on the clinical development of novel anti-cancer therapeutics. We were incorporated in Delaware in December 2000 as a subsidiary of Novogen Limited (ASX:NRT), an Australian company, and began trading on Nasdaq in December 2003. We relocated our headquarters from Sydney to San Diego in April 2010 following the appointment of Dr. Daniel Gold as Chief Executive Officer. In May 2011 we acquired Novogen's intellectual property portfolio, including rights to our lead oncology drug candidates ME-143 and ME-344. We received FDA approval of our Investigational New Drug (IND) application for ME-143 and initiated a Phase I clinical trial in September 2011.